merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safer option</answer>
<other>The article states Lilly is positioning its vials as a safer option than compounded drugs.</other>

<question_number>2</question_number>
<answer>LillyDirect offers similar delivery</answer>
<other>Both LillyDirect and telehealth companies deliver medication to patients' doors.</other>

<question_number>3</question_number>
<answer>Lack of oversight</answer>
<other>Compounded drugs are subject to far less oversight than traditionally approved medications.</other>

<question_number>4</question_number>
<answer>Regain market share</answer>
<other>Dr. Mackey suggests it's a signal to regain market share even if it means lower pricing.</other>

<question_number>5</question_number>
<answer>No space for compounders</answer>
<other>Jonsson states when off the shortage list, there should be no space for mass compounders.</other>

<question_number>6</question_number>
<answer>Removing third-party entities</answer>
<other>Lilly can offer transparent pricing by selling directly, removing third-party supply chain entities.</other>

<question_number>7</question_number>
<answer>Appeal to Medicare patients</answer>
<other>Fugh-Berman is concerned about the appeal to people on Medicare, which doesn't cover weight loss drugs.</other>

<question_number>8</question_number>
<answer>Safer perception</answer>
<other>Lilly is positioning its vials as a safer option than compounded drugs.</other>

<question_number>9</question_number>
<answer>In shortage</answer>
<other>Compounding pharmacies can make copycat versions of medications listed as "in shortage."</other>

<question_number>10</question_number>
<answer>Lower pricing</answer>
<other>Mackey suggests Lilly will get market share back through lower pricing.</other>